Policy & Regulation
InduPro secures strategic investment and collaboration with Sanofi to advance autoimmune therapy
10 December 2025 - Biotechnology company InduPro Inc announced on Wednesday that it has entered into a strategic equity investment and research collaboration with French healthcare company Sanofi S.A....
Innovent Biologics reports first participant dosed in Phase 1 trial of IBI3011
10 December 2025 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) announced on Tuesday that that the first participant has been dosed in the Phase 1 clinical trial of IBI3011, a...
D3 Bio completes USD108m Series B financing round
10 December 2025 - D3 Bio, a China-based global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced on Tuesday that it has comp...
Hemab Therapeutics announces positive Phase 2 multiple ascending dose study results for sutacimig
9 December 2025 - Denmark-based clinical-stage biotechnology company Hemab Therapeutics on Monday reported positive results from the completed Phase 2 multiple ascending dose (MAD) portion of its CL-1...
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
9 December 2025 - Cereno Scientific (Nasdaq First North: CRNO B), a Swedish biotech company developing treatments for rare cardiovascular and pulmonary diseases, announced on Monday that it has receiv...
Champions Oncology expands bioanalytical services with new technology and leadership
8 December 2025 - Champions Oncology Inc (NASDAQ:CSBR), a technology-enabled oncology research organisation, announced on Monday that it has expanded its clinical bioanalytical services with the integ...